Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial
Abstract In the coronavirus efficacy (COVE) phase 3 efficacy trial of the mRNA-1273 vaccine, IgG binding antibody (bAb) concentration against Spike (BA.1 strain) and neutralizing antibody (nAb) titer against Spike (BA.1 strain) pseudovirus were assessed as correlates of risk of Omicron COVID-19 and as correlates of relative boost efficacy in per-protocol recipients of a third (booster) dose. Markers were measured on the day of the boost (BD1) and 28 days later (BD29). For SARS-CoV-2 naive individuals, BD29 Spike IgG-BA.1 strain bAbs and BD29 BA.1-strain nAbs inversely correlated with Omicron COVID-19: hazard ratio (HR) per 10-fold marker increase [95% confidence interval (CI)] = 0.16 (0.03, 0.79); P=0.024 and 0.31 (0.10, 0.96); P = 0.042, respectively. These markers also inversely correlated with Omicron COVID-19 in non-naive individuals: HR = 0.15 (0.04, 0.63); P = 0.009 and 0.28 (0.07, 1.08); P = 0.06, trend. Fold-rise in markers from BD1 to BD29 had similarly strong inverse correlations. For SARS-CoV-2 naive individuals, overall booster relative (three-dose vs two-dose) efficacy was 46% (95% CI: 20%, 64%) and correlated with BA.1 strain nAb titer at exposure. At 56, 251, and 891 arbitrary units (AU)/ml (10th, 50th, and 90thpercentile), the booster relative efficacies were −8% (95% CI: −126%, 48%), 50% (25%, 67%), and 74% (49%, 87%), respectively. Similar relationships were observed for Spike IgG-BA.1 strain bAbs and for the markers measured at BD29. The performance of bAb and nAb markers as correlates of protection against Omicron COVID-19 supports their continued use as surrogate endpoints for mRNA vaccination against Omicron COVID-19..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 23. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Bo [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.10.15.23295628 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI04121000X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI04121000X | ||
| 003 | DE-627 | ||
| 005 | 20231224090656.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231017s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.10.15.23295628 |2 doi | |
| 035 | |a (DE-627)XBI04121000X | ||
| 035 | |a (biorXiv)10.1101/2023.10.15.23295628 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Bo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract In the coronavirus efficacy (COVE) phase 3 efficacy trial of the mRNA-1273 vaccine, IgG binding antibody (bAb) concentration against Spike (BA.1 strain) and neutralizing antibody (nAb) titer against Spike (BA.1 strain) pseudovirus were assessed as correlates of risk of Omicron COVID-19 and as correlates of relative boost efficacy in per-protocol recipients of a third (booster) dose. Markers were measured on the day of the boost (BD1) and 28 days later (BD29). For SARS-CoV-2 naive individuals, BD29 Spike IgG-BA.1 strain bAbs and BD29 BA.1-strain nAbs inversely correlated with Omicron COVID-19: hazard ratio (HR) per 10-fold marker increase [95% confidence interval (CI)] = 0.16 (0.03, 0.79); P=0.024 and 0.31 (0.10, 0.96); P = 0.042, respectively. These markers also inversely correlated with Omicron COVID-19 in non-naive individuals: HR = 0.15 (0.04, 0.63); P = 0.009 and 0.28 (0.07, 1.08); P = 0.06, trend. Fold-rise in markers from BD1 to BD29 had similarly strong inverse correlations. For SARS-CoV-2 naive individuals, overall booster relative (three-dose vs two-dose) efficacy was 46% (95% CI: 20%, 64%) and correlated with BA.1 strain nAb titer at exposure. At 56, 251, and 891 arbitrary units (AU)/ml (10th, 50th, and 90thpercentile), the booster relative efficacies were −8% (95% CI: −126%, 48%), 50% (25%, 67%), and 74% (49%, 87%), respectively. Similar relationships were observed for Spike IgG-BA.1 strain bAbs and for the markers measured at BD29. The performance of bAb and nAb markers as correlates of protection against Omicron COVID-19 supports their continued use as surrogate endpoints for mRNA vaccination against Omicron COVID-19. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Fong, Youyi |4 aut | |
| 700 | 1 | |a Fintzi, Jonathan |4 aut | |
| 700 | 1 | |a Chu, Eric |4 aut | |
| 700 | 1 | |a Janes, Holly E. |4 aut | |
| 700 | 1 | |a Carpp, Lindsay N. |0 (orcid)0000-0003-0333-5925 |4 aut | |
| 700 | 1 | |a Kenny, Avi |4 aut | |
| 700 | 1 | |a Carone, Marco |4 aut | |
| 700 | 1 | |a Benkeser, David |0 (orcid)0000-0002-1019-8343 |4 aut | |
| 700 | 1 | |a van der Laan, Lars W. P. |4 aut | |
| 700 | 1 | |a Deng, Weiping |4 aut | |
| 700 | 1 | |a Zhou, Honghong |4 aut | |
| 700 | 1 | |a Wang, Xiaowei |4 aut | |
| 700 | 1 | |a Lu, Yiwen |4 aut | |
| 700 | 1 | |a Yu, Chenchen |4 aut | |
| 700 | 1 | |a Borate, Bhavesh |4 aut | |
| 700 | 1 | |a Houchens, Christopher R. |4 aut | |
| 700 | 1 | |a Martins, Karen |4 aut | |
| 700 | 1 | |a Jayashankar, Lakshmi |4 aut | |
| 700 | 1 | |a Huynh, Chuong |4 aut | |
| 700 | 1 | |a Fichtenbaum, Carl J. |4 aut | |
| 700 | 1 | |a Kalams, Spyros |4 aut | |
| 700 | 1 | |a Gay, Cynthia L. |4 aut | |
| 700 | 1 | |a Andrasik, Michele P. |4 aut | |
| 700 | 1 | |a Kublin, James G. |4 aut | |
| 700 | 1 | |a Corey, Lawrence |4 aut | |
| 700 | 1 | |a Neuzil, Kathleen M. |4 aut | |
| 700 | 1 | |a Priddy, Frances |4 aut | |
| 700 | 1 | |a Das, Rituparna |4 aut | |
| 700 | 1 | |a Girard, Bethany |4 aut | |
| 700 | 1 | |a El Sahly, Hana M. |4 aut | |
| 700 | 1 | |a Baden, Lindsey R. |4 aut | |
| 700 | 1 | |a Donis, Ruben O. |4 aut | |
| 700 | 1 | |a Koup, Richard A. |4 aut | |
| 700 | 1 | |a Gilbert, Peter B. |4 aut | |
| 700 | 1 | |a Follmann, Dean |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 23. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:23 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.10.15.23295628 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 23 |c 12 | ||